Key result
Sarcopenia is linked to higher mortality in patients with chronic heart failure.
Why the study?
The significance of reduced skeletal muscle tissue (sarcopenia) on mortality and survival in patients with diagnosed heart failure was unclear.
Cross-Sectional (n=70)
May support sarcopenia screening for HF risk stratification; leaves open whether targeted interventions improve outcomes.
There is an increasing Heart failure (HF) population resulting from the higher number of myocardial infarction (MI) survivors, widespread presence of diabetes, hypertension, cardiac heart disease (CHD), obesity and other chronic conditions. Cardiac dysfunction is the main factor that lead to reduced physical activity in patients with HF. The alternations in skeletal musculature often are present in the background of HF and can also contribute to fatigue and dyspnea. Sarcopenia is reduction in muscle mass and force and is wright to say that it is one of the signs of “getting old”. The modern views on sarcopenia are that it is an outcome form number of medical, behavioral and ecological factors, which are common in older people. Together with sedentary life-style it can be the main reason for disability in late stages of human life. In our study we examined the significance of reduced skeletal muscle tissue on mortality and survival of patients with diagnosed HF.
No takes yet. Share an insight, caveat, or question.
Konstantin D. Gospodinov (2021) conducted a cross-sectional in Chronic Heart Failure (n=70). Sarcopenia (reduced skeletal muscle tissue density <35 H.U.) vs. No sarcopenia (muscle tissue density ≥35 H.U.) was evaluated on Survival and mortality rates. Reduced skeletal muscle tissue density (sarcopenia) was associated with a statistically significantly higher death rate and lower survival in patients with chronic heart failure compared to those without sarcopenia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: